The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial
Open accessAbstract
Background: Inflammation plays a crucial role in clinical manifestations and complications of acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has recently emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory properties. We sought to determine the potential usefulness of colchicine treatment in patients with ACS. Methods: This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hospitals in Australia that provide acute cardiac care service. Eligible participants were adults (18–85 years) who presented with ACS and had evidence of coronary artery disease on coronary angiography managed with either percutaneous coronary intervention or medical therapy. Patients were assigned to receive either colchicine (0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months) or placebo, in addition to standard secondary prevention pharmacotherapy, and were followed up for a minimum of 12 months. The primary outcome was a composite of all-cause mortality, ACS, ischemia-driven (unplanned) urgent revascularization, and noncardioembolic ischemic stroke in a time to event analysis. Results: A total of 795 patients were recruited between December 2015 and September 2018 (mean age, 59.8±10.3 years; 21% female), with 396 assigned to the colchicine group and 399 to the placebo group. Over the 12-month follow-up, there were 24 events in the colchicine group compared with 38 events in the placebo group ( P =0.09, log-rank). There was a higher rate of total death (8 versus 1; P =0.017, log-rank) and, in particular, noncardiovascular death in the colchicine group (5 versus 0; P =0.024, log-rank). The rates of reported adverse effects were not different (colchicine 23.0% versus placebo 24.3%), and they were predominantly gastrointestinal symptoms (colchicine, 23.0% versus placebo, 20.8%). Conclusions: The addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in patients with ACS and was associated with a higher rate of mortality. Registration: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12615000861550.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
Colchicine—Update on mechanisms of action and therapeutic uses
Leung, Y. Y., Yao Hui, L. L., & Kraus, V. B. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.06.013 · Cited by 950
Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., & Janzon, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu505 · Cited by 875
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Martínez, G. J., Celermajer, D. S., & Patel, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 342
Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome
Vaidya, K., Arnott, C., Martínez, G. J., Ng, B., McCormack, S., Sullivan, D. R., Celermajer, D. S., & Patel, S. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.08.013 · Cited by 300
Martínez, G. J., Robertson, S., Barraclough, J., Xia, Q., Mallat, Z., Bursill, C., Celermajer, D. S., & Patel, S. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002128 · Cited by 283
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study
Deftereos, S., Giannopoulos, G., Angelidis, C., Alexopoulos, N., Filippatos, G., Papoutsidakis, N., Sianos, G., Goudevenos, J., Alexopoulos, D., Pyrgakis, V., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.017611 · Cited by 279
Nidorf, M., & Thompson, P. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.039 · Cited by 201
Stewart, S., Yang, K. C. K., Atkins, K., Dalbeth, N., & Robinson, P. C. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-2120-7 · Cited by 180
Hennessy, T., Soh, L., Bowman, M., Kurup, R., Schultz, C., Patel, S., & Hillis, G. S. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.06.003 · Cited by 169
Mani, P., Puri, R., Schwartz, G. G., Nissen, S. E., Shao, M., Kastelein, J. J. P., Menon, V., Lincoff, A. M., & Nicholls, S. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0179 · Cited by 131
Colchicine for prevention of cardiovascular events
Hemkens, L. G., Ewald, H., Gloy, V., Arpagaus, A., Olu, K. K., Nidorf, M., Glinz, D., Nordmann, A. J., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011047.pub2 · Cited by 93
Chew, D. P., Amerena, J. V., Coverdale, S. G. M., et al. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb01847.x · Cited by 84
Self-citationNidorf, S. M., Eikelboom, J. W., & Thompson, P. L. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413499972 · Cited by 49
Colchicine in cardiovascular disease: an ancient drug with modern tricks
Tong, D. C., Wilson, A., & Layland, J. J. (2016) · Heart · doi:10.1136/heartjnl-2015-309211 · Cited by 36
Self-citationRisk of infections in patients with gout: a population-based cohort study
Spaetgens, B., de Vries, F., Driessen, J. H. M., Leufkens, H. G. M., Souverein, P. C., Boonen, A. E. R. C. H., van der Meer, J. W. M., & Joosten, L. A. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-01588-5 · Cited by 30
Cited by
The Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02391-6 · Cited by 445
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Metadata
- Authors
- Tong, D. C., Quinn, S., Nasis, A., Hiew, C., Roberts-Thomson, P., Adams, H., Sriamareswaran, R., Htun, N. M., Wilson, W., Stub, D., van Gaal, W., Howes, L., Collins, N., Yong, A., Bhindi, R., Whitbourn, R., Lee, A., Hengel, C., Asrress, K., Freeman, M., Amerena, J., Wilson, A., & Layland, J.
- Venue
- Circulation
- Published
- 2020-11-17
- Volume
- 142
- Issue
- 20
- Pages
- 1890-1900
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3082109297
- Cited by
- 393
- References
- 24
- FWCI
- 27.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.